Stem Cell, Tissue Engineering and Regenerative Medicine

Greene is a residency and fellowship-trained orthopedic surgeon who has shifted completely into business. He started a healthcare internet marketing company, US Lead Network, that helps medical and dental practices acquire patients on the web in a pay-for-performance manner. The company is now using Artificial Intelligence for marketing which is lowering the cost per lead substantially. He has written two books on Healthcare Internet Marketing that are available for purchase on Amazon. He has been featured as a Top 20 Expert Author by Ezines.com, the top article directory site in the world. Out of over 470,000 authors, Greene ranks #15 as an Expert Author and #1 in the Pain Management category. He also started a regenerative medicine company, R3 Stem Cell, that offers marketing, an IRB-approved protocol, and top products for practices nationwide. R3 offers stem cell training courses that are second to none at https://stemcelltrainingcourse.org

Ashok Srivastava is the Chief Medical Officer of Trans Atlantic Therapeutics  Oncology,   He was the Chief Medical Officer of CareBeyond - A Radiation Therapy Cancer Center, New Jersey, USA. He has more than 15 years of experience in drug development, medical affairs, and commercialization of cancer drugs including radiopharmaceutical and supportive care; Phase I – 4, and marketing commercialization of  Hematology, Oncology, and radiopharmaceutical drugs in the USA, EU, and Japan.  He is the leader in Cancer Drug Development  Worldwide large and complex Phase 3 Clinical Trials in many countries.  He contributed to 21-INDs and 7-NDAs of Cancer Drugs, the acquisition /merger of a company and drug for more than $300 million. He received his clinical, and medical training  & worked at renowned medical centers and pharmaceutical institutions worldwide; Walter Reed Army Institute of Research and Medical Center,  Daiichi, Sumitomo, Pharmacia, Pfizer, Eisai Oncology, and Spectrum Pharmaceuticals. He received his Clinical, Medical & Business educations from All India Institute of Medical Sciences, New Delhi, India; the Academy of Medical Sciences, Czechoslovakia; the School of Medicine Nagasaki University, Japan, and Pharmaceutical Business at Rutgers University Business Management, New Jersey, USA. He played a key role in a dramatic expansion of oncology drug–developed cancer drugs- Sutent (Sunitinib), Evoxac (Cevimeline HCl), and liposomal doxorubicin (Myocet) in combination with Herceptin & Paclitaxel for HER2 positive metastatic breast cancer patients and latuda (Lurasidone) for schizophrenia   He is one of the inventors of Japanese encephalitis vaccine (IXIARO). He has published more than 85 papers in National and International Journals, more than 120 abstracts, 3 book chapters, and 2 patents. He is the recipient of numerous National & International prestigious medical awards and recognitions from the United Nations, Ministry of  Health, Japan, Department of Army, Walter Reed Army Medical Center, and Walter Reed Army Institute of Research, Washington DC, USA. He served as a medical advisor to Poniard Pharmaceutical for small-cell lung cancer in the USA, EU, and India. Srivastava is a member of numerous prestigious organizations; America’s Top Oncologist of the years 2007, 2008, and 2011, Breast Cancer Foundation, Indian Society of Oncology, American Society of Clinical Oncology, American Society for Therapeutic Radiology & Oncology, American Association of Cancer Research, and International Society of Lung Cancer.  Dr. Srivastava is a strategic medical advisor and Board Member to several pharma in the USA for clinical, regulatory, and supervises cancer drug development. Recently Dr. Srivastava was awarded membership in Japan External Trade  Organization, USA. Dr. Srivastava is a Leader in Drug Safety, pharmacovigilance of  Oncology, hematology, and immuno-oncology and built global drug safety and pharmacovigilance companies in the USA, and India. Dr. Srivastava was invited as an honorable speaker at the drug safety & Pharmacovigilance congress in London, UK, China, India, and Washington, DC, USA in Jan 2012, 2013, and 2017.  Dr. Srivastava brought 2 cancer drugs & a vaccine to a global market for approx  3 – 3.5 billion $ in global sales.  He serves on the board of directors for oncology virtual pharma companies in the USA. He is on the Board of advisors to Calidi Biotherapeutics. 

Lucia Ceresa has Extensive international professional experience, demonstrated capabilities, a proven track record, and expertise in promoting sales strategy and marketing programs. & Manages quality, regulatory, and compliance projects with multiple competing priorities having a direct impact on commercial opportunity. She Develops strategies for governmental approval to introduce new products to market, Broad capabilities and experience in all aspects of validation, quality control, and addressing the challenges of the pharmaceutical manufacturing process. She has  Extensive industry experience with regulatory bodies and agencies regarding documentation for the submission and approval process. Lucia's Expertise from the initial R&D project phase through the final product release for commercialization.

Maurizio Serafini completed Degree in Medicine and Surgery in University of Chieti Gabriele D’Annunzio in 1985. He is a Dental Practitioner, Chieti. Mostly involved in implant-prosthetic rehabilitation in patients with bone atrophy, with personal case studies in the technique of intraoral bone graft and use of mitogenic agents &/O growth factors: PRP, aimed at an excellent aesthetic result. Professor, 2014 and 2011 at Master in Oral Implantology and Prosthodontics, University of Bari. 2005-2008 Tutor and Research Scientist for Alpha-Bio. 1997-2003 Participated with the team of Prof. P. Morselli in sagittal osteotomy combined surgery to resolve Ortognatodontic severe problems, at "Villa Castiglione" private clinic in Bologna. Maurizio Serafini published 12 posters and 10 publications in International Journal, I currently participated at many International Congress of Medicine and Dentistry about Growth Factor. Elected to the World’s Top 100 Doctors, Class 2022.

Sergey Suchkov was born in the City of Astrakhan, Russia, in a family of dynasty medical doctors. In 1980, graduated from Astrakhan State Medical University and was awarded MD. In 1985, Suchkov maintained his Ph.D. as a Ph.D. student of the I.M. Sechenov Moscow Medical Academy and Institute of Medical Enzymology. In 2001, Suchkov maintained his Doctor Degree at the National Institute of Immunology, Russia. From 1989 through 1995, Suchkov was being the Head of the Lab of Clinical Immunology, at Helmholtz Eye Research Institute in Moscow. From 1995 through 2004 - a Chair of the Dept for Clinical Immunology, Moscow Clinical Research Institute (MONIKI). From 1993-1996, Suchkov was a Secretary-in-Chief of the Editorial Board, of Biomedical Science, an international journal published jointly by the USSR Academy of Sciences and the Royal Society of Chemistry, UK.
At present, Sergey Suchkov is:

1. Professor and Chair, Dept for Personalized Medicine, Precision Nutriciology and Biodesign, the Institute for Biotech & Global Medicine of RosBioTech, Moscow, Russia
2. Professor, Dept for Clinical Immunology, A.I. Evdokimov Moscow State University of Medical and Dentistry, Moscow, Russia
3. Member, New York Academy of Sciences, USA
4. Secretary General, United Cultural Convention (UCC), Cambridge, UK

Suchkov is a member of the:

1. American Chemical Society (ACS), USA;
2. American Heart Association (AHA), USA;
3. European Association for Medical Education (AMEE), Dundee, UK;
4. EPMA (European Association for Predictive, Preventive and Personalized Medicine), Brussels, EU;
5. ARVO (American Association for Research in Vision and Ophthalmology);
6. ISER (International Society for Eye Research);
7. Personalized Medicine Coalition (PMC), Washington, DC, USA
8. All-Union (from 1992 - Russian) Biochemical Society;
9. All-Union (from 1992 - Russian) Immunological Society.

Suchkov is a member of the Editorial Boards of “Open Journal of Immunology”, EPMA J., American J. of Cardiovascular Research, and “Personalized Medicine Universe”

Pallavi Dhillon, PharmD, Ph.D., is working at ClinFomatrix, NJ, USA, and New Delhi, India, and Trans Atlantic Therapeutics, New Jersey, USA,  Director and Head of Clinical Operations and Drug Safety, USA, for more than 5 years and managing drug safety program globally, Quality Review of ICSRs, write and review safety narratives, pharmacovigilance Control document, monitoring of the compliance of outsourced pharmacovigilance activities. Lead concepts of quality management and inspection readiness within the study Clinical project monitoring and management to ensure that clinical trial project and process work was conducted to internal and external standards. This included ensuring that all colleagues, both internal as well as preferred CROs and partners, were regulatory inspection ready and staff were compliant with ICH GCP and relevant national and international regulations and guidelines and corporate policies and SOPs. Conducting clinical site feasibility studies as well as clinical site identification starting from Phase-I to Phase IV. Monitoring the clinical sites as per the monitoring plan to ensure that Principal Investigator(s) are conducting the study as per Protocol, ICH-GCP & SOPs. Pallavi Dhillon have experience in neuroscience drug development and safety: schizophrenia, depression, mania, bipolar disorder, pediatric bipolar, pediatric schizophrenia, neuropathic pain, inflammation; osteoarthritis in CNS patients. Pallavi Dhillon also have significant experience in Oncology: Phase 1-3 clinical trials, Solid tumor studies; lung cancers, head and neck, breast, liver, colorectal, prostate, and ovarian; hematologic tumors, leukemia, and myeloma blood disorders. Pallavi Dhillon also led the Cardiovascular: Lipid studies, Women's health: Osteoporosis; migraine, non-interventional studies, Infectious disease: HIV/AIDs; vaccine; upper respiratory tract infections, pediatric sinusitis, Specialty Care/Other Therapy Areas: Inflammation, rheumatology, urology. Pallavi Dhillon completed my doctor of philosophy, master and Bachelor's in pharmacy, at MDU Rohtak, India. Pallavi Dhillon worked at leading pharmaceutical companies; Baxter Healthcare India, Pharmacovigilance Specialist, India, and Pfizer Pharmacovigilance Officer, New Delhi, India, and was responsible for all AEs, SAEs, medication errors, and product complaints. Differentiating between Initial and Follow-up reports using ARGUS Working on database Pfoenix and ARGUS for comparison of Adverse Events and completing follow-up reports. QC of cases, AEM report forms for any kind of errors. Undergo client mentorship as designated by the project manager. I also worked as Clinical Research Associate, at Sir Ganga Ram Hospital, New Delhi, and managed phase 3 protocols, recruitment, patient screening, patient consent forms and follow-up management with Investigator. Maintained source documentation and drug accountability, SAEs reporting, maintained site master file. HIPPA inclusions for IRB/IEC submission. Pallavi Dhillon was a Trainee Clinical Research Associate, at Clinsys CRO, Noida, India and Assisted in the conduction of BA/BE studies. To prepare readiness of the clinical facility and all study/system-related documents for the audit process (QA audit, any regulatory Sponsor audit, etc) at all / times. Pallavi Dhillon completed an internship at Clinsys Clinical Research Organization as, Clinical Research Coordinator, Retention/recruitment Patients in India. Pallavi Dhillon am a member of the Pharmacy Associations of India and a registered pharmacist in India.

Teterina Anastasia, Ph.D. of technical sciences, 2017. The main scientific results are in the field of creating biocompatible materials for use in various fields of medicine (replacement and plasty of bone defects; means of localized and prolonged delivery of drugs into the body; regenerative medicine; coatings on metal implants). In addition to scientific work and research, he manages grants and projects, teaches, and reads courses of lectures, and tutors students and graduate students in the performance of scientific and practical activities.

Polina Smirnova (maiden name Polina Mikheeva till 2021) has experience in the field of obtaining biocompatible materials for bone tissue engineering, and chemical synthesis of bioactive coatings and materials, including low-temperature methods. She has considerable experience in investigations and processing of visualization data obtained using electron microscopy, X-ray diffraction, IR-spectroscopy, and computed tomography methods

Igor Smirnov has experience in the field of obtaining biocompatible materials for bone tissue engineering, and chemical synthesis of bioactive coatings and materials, including low-temperature methods. He has considerable experience in investigations and processing of visualization data obtained using electron microscopy, X-ray diffraction, IR-spectroscopy, and computed tomography methods

Antrea-Antriana Psaraki has extensive expertise in the field of stem cells and extracellular vesicles and their applications in regenerative medicine, aiming for more precise and effective treatments for liver diseases. She conducted an experimental approach, revealing the proteomic cargo and the therapeutic mechanism of exosomes derived from fetal MSCs in a mouse model of AHF. This specific model has been designed after years of experience in research and training in cell culture procedures, especially in the application of MSC-mediators (exosomes and CM) in liver diseases (Psaraki et al., 2022; Nikokiraki et al., 2022). The methodology that was followed was based on established procedures (Zagoura et al. 2012), as well as on findings, on the anti-inflammatory and regenerative role of MSC-secretome in AHF (Zagoura et al. 2019) and inflammatory bowel disease (IBD)

Alice Colescu is a 4th-year medical student in Iasi, Romania. She is part of the HPHR team and is also a fellow research assistant at Humanitas University, Milan. Her motto: Always have high hopes. Dreams can come true if you dare to pursue them. 
 

Mamata Mishra has completed her Ph.D. at National Brain Research Centre, in INDIA. She has 5 years of post-Doctoral research at Temple University, Philadelphia, PA, USA, and IISC., JNCASR, Bangalore, INDIA. She worked as the head of the Stem Cell Laboratory, in Navi Mumbai, India for 4 years and is currently as Senior Research Scientist, at JAI RESEARCH FOUNDATION, Gujarat, India. She has 26 international publications that have been cited over 692 times, and her publication h-index is 19. She has an international award from the International Society of Neurovirology (ISNV) in San Diego, USA as Young-investigator and she has the ‘Best Paper published” award from the Indian Academy of Neuroscience, India. She has been serving as an editorial board member of several peer-reviewed reputed journals.